Gilead Sciences (GILD) Assets Average (2009 - 2026)
Gilead Sciences' (GILD) quarterly Assets Average came in at $57.7 billion in Q1 2026, little changed YoY from $57.7 billion in Q1 2025, and down 1.92% on a QoQ basis from $58.8 billion in Q4 2025.
Gilead Sciences (GILD) Assets Average (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Assets Average data on file, last reported at $57.7 billion in Q1 2026.
- Quarterly Assets Average changed 0.11% year-over-year to $57.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 billion (changed 0.11% YoY) and the FY2025 annual result came in at $59.0 billion, down 2.56% from the prior year.
- Assets Average fell to $57.7 billion in Q1 2026, from $58.8 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $65.5 billion in Q1 2022 to a low of $54.1 billion in Q3 2024.
- A 5-year average of $59.7 billion and a median of $59.2 billion in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average decreased 13.32% — and 2025, when it increased 5.69%.
- Tracing GILD's Assets Average over 5 years: stood at $62.9 billion in 2022, then retreated by 0.98% to $62.2 billion in 2023, then slipped by 8.82% to $56.8 billion in 2024, then increased by 3.56% to $58.8 billion in 2025, then declined by 1.92% to $57.7 billion in 2026.
- The last three Assets Average figures came in at $57.7 billion (Q1 2026), $58.8 billion (Q4 2025), and $57.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.82 Bn |
| Mar 31, 2026 | 57.65 Bn |
| Dec 31, 2025 | 58.78 Bn |
| Sep 30, 2025 | 57.13 Bn |
| Jun 30, 2025 | 56.08 Bn |
| Mar 31, 2025 | 57.71 Bn |
| Dec 31, 2024 | 56.76 Bn |
| Sep 30, 2024 | 54.05 Bn |
| Jun 30, 2024 | 54.94 Bn |
| Mar 31, 2024 | 59.21 Bn |
| Dec 31, 2023 | 62.25 Bn |
| Sep 30, 2023 | 62.36 Bn |
| Jun 30, 2023 | 62.11 Bn |
| Mar 31, 2023 | 62.52 Bn |
| Dec 31, 2022 | 62.86 Bn |
| Sep 30, 2022 | 62.71 Bn |
| Jun 30, 2022 | 62.98 Bn |
| Mar 31, 2022 | 65.52 Bn |
| Dec 31, 2021 | 67.53 Bn |
| Sep 30, 2021 | 67.54 Bn |